Search

Your search keyword '"Donnelly, J Peter"' showing total 525 results
Start Over Author "Donnelly, J Peter"
525 results on '"Donnelly, J Peter"'

1. When to change treatment of acute invasive aspergillosis: an expert viewpoint

Author

Slavin, Monica A, Chen, Yee-Chun, Cordonnier, Catherine, Cornely, Oliver A, Cuenca-Estrella, Manuel, Donnelly, J Peter, Groll, Andreas H, Lortholary, Olivier, Marty, Francisco M, Nucci, Marcio, Rex, John H, Rijnders, Bart JA, Thompson, George R, Verweij, Paul E, White, P Lewis, Hargreaves, Ruth, Harvey, Emma, and Maertens, Johan A

Subjects
Infectious Diseases, Clinical Trials and Supportive Activities, Rare Diseases, Clinical Research, Evaluation of treatments and therapeutic interventions, 6.1 Pharmaceuticals, Infection, Antifungal Agents, Aspergillosis, Bronchoalveolar Lavage Fluid, Humans, Immunocompromised Host, Invasive Fungal Infections, Invasive Pulmonary Aspergillosis, Mannans, Microbiology, Medical Microbiology, Pharmacology and Pharmaceutical Sciences
Abstract

Invasive aspergillosis (IA) is an acute infection affecting patients who are immunocompromised, as a result of receiving chemotherapy for malignancy, or immunosuppressant agents for transplantation or autoimmune disease. Whilst criteria exist to define the probability of infection for clinical trials, there is little evidence in the literature or clinical guidelines on when to change antifungal treatment in patients who are receiving prophylaxis or treatment for IA. To try and address this significant gap, an advisory board of experts was convened to develop criteria for the management of IA for use in designing clinical trials, which could also be used in clinical practice. For primary treatment failure, a change in antifungal therapy should be made: (i) when mycological susceptibility testing identifies an organism from a confirmed site of infection, which is resistant to the antifungal given for primary therapy, or a resistance mutation is identified by molecular testing; (ii) at, or after, 8 days of primary antifungal treatment if there is increasing serum galactomannan, or galactomannan positivity in serum, or bronchoalveolar lavage fluid when the antigen was previously undetectable, or there is sudden clinical deterioration, or a new clearly distinct site of infection is detected; and (iii) at, or after, 15 days of primary antifungal treatment if the patient is clinically stable but with ≥2 serum galactomannan measurements persistently elevated compared with baseline or increasing, or if the original lesions on CT or other imaging, show progression by >25% in size in the context of no apparent change in immune status.

Published
2021

2. Revision and Update of the Consensus Definitions of Invasive Fungal Disease From the European Organization for Research and Treatment of Cancer and the Mycoses Study Group Education and Research Consortium

Author

Donnelly, J Peter, Chen, Sharon C, Kauffman, Carol A, Steinbach, William J, Baddley, John W, Verweij, Paul E, Clancy, Cornelius J, Wingard, John R, Lockhart, Shawn R, Groll, Andreas H, Sorrell, Tania C, Bassetti, Matteo, Akan, Hamdi, Alexander, Barbara D, Andes, David, Azoulay, Elie, Bialek, Ralf, Bradsher, Robert W, Bretagne, Stephane, Calandra, Thierry, Caliendo, Angela M, Castagnola, Elio, Cruciani, Mario, Cuenca-Estrella, Manuel, Decker, Catherine F, Desai, Sujal R, Fisher, Brian, Harrison, Thomas, Heussel, Claus Peter, Jensen, Henrik E, Kibbler, Christopher C, Kontoyiannis, Dimitrios P, Kullberg, Bart-Jan, Lagrou, Katrien, Lamoth, Frédéric, Lehrnbecher, Thomas, Loeffler, Jurgen, Lortholary, Olivier, Maertens, Johan, Marchetti, Oscar, Marr, Kieren A, Masur, Henry, Meis, Jacques F, Morrisey, C Orla, Nucci, Marcio, Ostrosky-Zeichner, Luis, Pagano, Livio, Patterson, Thomas F, Perfect, John R, Racil, Zdenek, Roilides, Emmanuel, Ruhnke, Marcus, Prokop, Cornelia Schaefer, Shoham, Shmuel, Slavin, Monica A, Stevens, David A, Thompson, George R, Vazquez, Jose A, Viscoli, Claudio, Walsh, Thomas J, Warris, Adilia, Wheat, L Joseph, White, P Lewis, Zaoutis, Theoklis E, and Pappas, Peter G

Subjects
Biomedical and Clinical Sciences, Clinical Sciences, Cancer, Prevention, Clinical Research, Good Health and Well Being, Antifungal Agents, Consensus, Humans, Immunocompromised Host, Invasive Fungal Infections, Mycoses, Neoplasms, consensus, definitions, invasive fungal diseases, diagnosis, research, Biological Sciences, Medical and Health Sciences, Microbiology, Clinical sciences
Abstract

BackgroundInvasive fungal diseases (IFDs) remain important causes of morbidity and mortality. The consensus definitions of the Infectious Diseases Group of the European Organization for Research and Treatment of Cancer and the Mycoses Study Group have been of immense value to researchers who conduct clinical trials of antifungals, assess diagnostic tests, and undertake epidemiologic studies. However, their utility has not extended beyond patients with cancer or recipients of stem cell or solid organ transplants. With newer diagnostic techniques available, it was clear that an update of these definitions was essential.MethodsTo achieve this, 10 working groups looked closely at imaging, laboratory diagnosis, and special populations at risk of IFD. A final version of the manuscript was agreed upon after the groups' findings were presented at a scientific symposium and after a 3-month period for public comment. There were several rounds of discussion before a final version of the manuscript was approved.ResultsThere is no change in the classifications of "proven," "probable," and "possible" IFD, although the definition of "probable" has been expanded and the scope of the category "possible" has been diminished. The category of proven IFD can apply to any patient, regardless of whether the patient is immunocompromised. The probable and possible categories are proposed for immunocompromised patients only, except for endemic mycoses.ConclusionsThese updated definitions of IFDs should prove applicable in clinical, diagnostic, and epidemiologic research of a broader range of patients at high-risk.

Published
2020

3. Polymerase Chain Reaction on Respiratory Tract Specimens of Immunocompromised Patients to Diagnose Pneumocystis Pneumonia: A Systematic Review and Meta-analysis

Author

Brown, Lottie, primary, Rautemaa-Richardson, Riina, additional, Mengoli, Carlo, additional, Alanio, Alexandre, additional, Barnes, Rosemary A, additional, Bretagne, Stéphane, additional, Chen, Sharon C A, additional, Cordonnier, Catherine, additional, Donnelly, J Peter, additional, Heinz, Werner J, additional, Jones, Brian, additional, Klingspor, Lena, additional, Loeffler, Juergen, additional, Rogers, Thomas R, additional, Rowbotham, Eleanor, additional, White, P Lewis, additional, and Cruciani, Mario, additional

Published
2024
Full Text
View/download PDF

4. Mycobacterial infections in adults with haematological malignancies and haematopoietic stem cell transplants: guidelines from the 8th European Conference on Infections in Leukaemia

Author

Greinix, Hildegard, Maertens, Johan, De Greef, Julien, Slavin, Monica, Spriet, Isabel, Hubacek, Petr, Bergeron, Anne, Cordonnier, Catherine, Kanerva, Jukka, Herbrecht, Raoul, Herrmann, Jean-Louis, Lanternier, Fanny, Bondeelle, Louise, Robin, Christine, Einsele, Hermann, Lehrnbecher, Thomas, Groll, Andreas, Maschmeyer, Georg, Lange, Christoph, von Lilienfeld-Toal, Marie, Pana, Dorothea, Roilides, Emmanuel, Kassa, Csaba, Averbuch, Diana, Engelhard, Dan, Cesaro, Simone, Mikulska, Malgorzata, Pagano, Livio, Castagnola, Elio, Compagno, Francesca, Goletti, Delia, Mesini, Alessio, Donnelly, Peter J, Styczynski, Jan, Botelho de Sousa, Aida, Aljurf, Mahmoud, de la Camara, Rafael, Navarro, David, Rovira, Montserrat, Franquet, Tomas, Garcia-Vidal, Carol, Ljungman, Per, Paukssen, Karlis, Ammann, Roland, Lamoth, Frédéric, Hirsch, Hans, Ritz, Nicole, Akova, Murat, Ceesay, Mansour, Warris, Adilia, Chemaly, Roy, and Donnelly, J Peter

Published
2022
Full Text
View/download PDF

6. An Overview of Systematic Reviews of Polymerase Chain Reaction (PCR) for the Diagnosis of Invasive Aspergillosis in Immunocompromised People: A Report of the Fungal PCR Initiative (FPCRI)—An ISHAM Working Group

Author

Cruciani, Mario, primary, White, P. Lewis, additional, Barnes, Rosemary A., additional, Loeffler, Juergen, additional, Donnelly, J. Peter, additional, Rogers, Thomas R., additional, Heinz, Werner J., additional, Warris, Adilia, additional, Morton, Charles Oliver, additional, Lengerova, Martina, additional, Klingspor, Lena, additional, Sendid, Boualem, additional, and Lockhart, Deborah E. A., additional

Published
2023
Full Text
View/download PDF

9. Empiric vs Preemptive Antifungal Strategy in High-Risk Neutropenic Patients on Fluconazole Prophylaxis: A Randomized Trial of the European Organization for Research and Treatment of Cancer

Author

Maertens, Johan, Lodewyck, Tom, Donnelly, J Peter, Chantepie, Sylvain, Robin, Christine, Blijlevens, Nicole, Turlure, Pascal, Selleslag, Dominik, Baron, Frederic, Aoun, Mickael, Heinz, Werner J, Bertz, Hartmut, Racil, Zdenek, Vandercam, Bernard, Drgona, Lubos, Coiteux, Valerie, Llorente, Cristina Castilla, Schaefer-Prokop, Cornelia, Paesmans, Marianne, Ameye, Lieveke, Meert, Liv, Cheung, Kin Jip, Hepler, Deborah A, Loeffler, Juergen, Barnes, Rosemary, Marchetti, Oscar, Verweij, Paul, Lamoth, Frederic, Bochud, Pierre-Yves, Schwarzinger, Michael, and Cordonnier, Catherine

Subjects
Microbiology (medical), empiric, Science & Technology, Immunology, lnfectious Diseases and Global Health Radboud Institute for Molecular Life Sciences [Radboudumc 4], FEBRILE, STEM-CELL TRANSPLANTS, Microbiology, THERAPY, PERSISTENT FEVER, preemptive, CIRCULATING GALACTOMANNAN, All institutes and research themes of the Radboud University Medical Center, Infectious Diseases, galactomannan, neutropenia, COMPUTED-TOMOGRAPHY, INVASIVE FUNGAL-INFECTION, LIPOSOMAL AMPHOTERICIN-B, ASPERGILLOSIS, Life Sciences & Biomedicine, HEMATOLOGY PATIENTS, antifungal, Rare cancers Radboud Institute for Health Sciences [Radboudumc 9]
Abstract

Background Empiric antifungal therapy is considered the standard of care for high-risk neutropenic patients with persistent fever. The impact of a preemptive, diagnostic-driven approach based on galactomannan screening and chest computed tomography scan on demand on survival and on the risk of invasive fungal disease (IFD) during the first weeks of high-risk neutropenia is unknown. Methods Patients with acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS) and allogeneic hematopoietic cell transplant recipients were randomly assigned to receive caspofungin empirically (arm A) or preemptively (arm B), while receiving fluconazole 400 mg daily prophylactically. The primary end point of this noninferiority study was overall survival (OS) 42 days after randomization. Results Of 556 patients recruited, 549 were eligible: 275 in arm A and 274 in arm B. Eighty percent of the patients had AML or MDS requiring high-dose chemotherapy, and 93% of them were in the first induction phase. At day 42, the OS was not inferior in arm B (96.7%; 95% confidence interval [CI], 93.8%–98.3%) when compared with arm A (93.1%; 95% CI, 89.3%–95.5%). The rates of IFDs at day 84 were not significantly different, 7.7% (95% CI, 4.5%–10.8%) in arm B vs 6.6% (95% CI, 3.6%–9.5%) in arm A. The rate of patients who received caspofungin was significantly lower in arm B (27%) than in arm A (63%; P < .001). Conclusions The preemptive antifungal strategy was safe for high-risk neutropenic patients given fluconazole as prophylaxis, halving the number of patients receiving antifungals without excess mortality or IFDs. Clinical Trials Registration. NCT01288378; EudraCT 2010-020814-27.

Published
2022

10. Risk stratification in febrile neutropenic episodes in adolescent/young adult patients with cancer

Author

Haeusler, Gabrielle M., Bauters, Tiene, Laureys, Geneviève, Spassova, Maria, Klaassen, Robert, Alexander, Sarah, Silva, Pamela, Tordecilla, Juan, Paesmans, Marianne, Donnelly, J. Peter, Simon, Arne, Hann, Ian M., Ranasinghe, Neil, Riley, Richard D., Chisholm, Julia, Yeomanson, Daniel, Sutton, Alex J., Dommett, Rachel, Gupta, Ajay, Castagnola, Elio, Haupt, Ricarrdo, Meidema, Karin, Kuehne, Thomas, Kitanovski, Lidija, Niggli, Felix, Nadal, David, Tezcan, Gulsun, Hakim, Hana, Stryjewski, Glen, Phillips, Robert S., Bhuller, Kaljit, Sung, Lillian, Ammann, Roland A., Tissing, Wim J.E., Lehrnbecher, Thomas, and Stewart, Lesley A.

Published
2016
Full Text
View/download PDF

12. International expert opinion on the management of infection caused by azole-resistant Aspergillus fumigatus

Author

Verweij, Paul E., Ananda-Rajah, Michelle, Andes, David, Arendrup, Maiken C., Brüggemann, Roger J., Chowdhary, Anuradha, Cornely, Oliver A., Denning, David W., Groll, Andreas H., Izumikawa, Koichi, Kullberg, Bart Jan, Lagrou, Katrien, Maertens, Johan, Meis, Jacques F., Newton, Pippa, Page, Iain, Seyedmousavi, Seyedmojtaba, Sheppard, Donald C., Viscoli, Claudio, Warris, Adilia, and Donnelly, J. Peter

Published
2015
Full Text
View/download PDF

13. Mycobacterial infections in adults with haematological malignancies and haematopoietic stem cell transplants: guidelines from the 8th European Conference on Infections in Leukaemia

Author

Bergeron, Anne, primary, Mikulska, Malgorzata, additional, De Greef, Julien, additional, Bondeelle, Louise, additional, Franquet, Tomas, additional, Herrmann, Jean-Louis, additional, Lange, Christoph, additional, Spriet, Isabel, additional, Akova, Murat, additional, Donnelly, J Peter, additional, Maertens, Johan, additional, Maschmeyer, Georg, additional, Rovira, Montserrat, additional, Goletti, Delia, additional, de la Camara, Rafael, additional, Greinix, Hildegard, additional, Slavin, Monica, additional, Hubacek, Petr, additional, Bergeron, Anne, additional, Cordonnier, Catherine, additional, Kanerva, Jukka, additional, Herbrecht, Raoul, additional, Lanternier, Fanny, additional, Robin, Christine, additional, Einsele, Hermann, additional, Lehrnbecher, Thomas, additional, Groll, Andreas, additional, von Lilienfeld-Toal, Marie, additional, Pana, Dorothea, additional, Roilides, Emmanuel, additional, Kassa, Csaba, additional, Averbuch, Diana, additional, Engelhard, Dan, additional, Cesaro, Simone, additional, Pagano, Livio, additional, Castagnola, Elio, additional, Compagno, Francesca, additional, Mesini, Alessio, additional, Donnelly, Peter J, additional, Styczynski, Jan, additional, Botelho de Sousa, Aida, additional, Aljurf, Mahmoud, additional, Navarro, David, additional, Garcia-Vidal, Carol, additional, Ljungman, Per, additional, Paukssen, Karlis, additional, Ammann, Roland, additional, Lamoth, Frédéric, additional, Hirsch, Hans, additional, Ritz, Nicole, additional, Ceesay, Mansour, additional, Warris, Adilia, additional, and Chemaly, Roy, additional

Published
2022
Full Text
View/download PDF

16. Application of the 2008 Definitions for Invasive Fungal Diseases to the Trial Comparing Voriconazole Versus Amphotericin B for Therapy of Invasive Aspergillosis: A Collaborative Study of the Mycoses Study Group (MSG 05) and the European Organization for Research and Treatment of Cancer Infectious Diseases Group

Author

Herbrecht, Raoul, Patterson, Thomas F., Slavin, Monica A., Marchetti, Oscar, Maertens, Johan, Johnson, Elizabeth M., Schlamm, Haran T., Donnelly, J. Peter, and Pappas, Peter G.

Published
2015

21. Response to Rituximab-Based Therapy and Risk Factor Analysis in Epstein Barr Virus—Related Lymphoproliferative Disorder After Hematopoietic Stem Cell Transplant in Children and Adults: A Study From the Infectious Diseases Working Party of the European Group for Blood and Marrow Transplantation

Author

Infectious Diseases Working Party of the European Group for Blood and Marrow Transplantation, Styczynski, Jan, Gil, Lidia, Tridello, Gloria, Ljungman, Per, Donnelly, J. Peter, van der Velden, Walter, Omar, Hamdy, Martino, Rodrigo, Halkes, Constantijn, Faraci, Maura, Theunissen, Koen, Kalwak, Krzysztof, Hubacek, Petr, Sica, Simona, Nozzoli, Chiara, Fagioli, Franca, Matthes, Susanne, Diaz, Miguel A., Migliavacca, Maddalena, Balduzzi, Adriana, Tomaszewska, Agnieszka, de la Camara, Rafael, van Biezen, Anja, Hoek, Jennifer, Iacobelli, Simona, Einsele, Hermann, and Cesaro, Simone

Published
2013
Full Text
View/download PDF

22. When to change treatment of acute invasive aspergillosis: an expert viewpoint

Author

Slavin, Monica A., Chen, Yee-Chun, Cordonnier, Catherine, Cornely, Oliver A., Cuenca-Estrella, Manuel, Donnelly, J. Peter, Groll, Andreas H., Lortholary, Olivier, Marty, Francisco M., Nucci, Marcio, Rex, John H., Rijnders, Bart J. A., Thompson, George R., Verweij, Paul E., White, P. Lewis, Hargreaves, Ruth, Harvey, Emma, Maertens, Johan A., Slavin, Monica A., Chen, Yee-Chun, Cordonnier, Catherine, Cornely, Oliver A., Cuenca-Estrella, Manuel, Donnelly, J. Peter, Groll, Andreas H., Lortholary, Olivier, Marty, Francisco M., Nucci, Marcio, Rex, John H., Rijnders, Bart J. A., Thompson, George R., Verweij, Paul E., White, P. Lewis, Hargreaves, Ruth, Harvey, Emma, and Maertens, Johan A.

Abstract

Invasive aspergillosis (IA) is an acute infection affecting patients who are immunocompromised, as a result of receiving chemotherapy for malignancy, or immunosuppressant agents for transplantation or autoimmune disease. Whilst criteria exist to define the probability of infection for clinical trials, there is little evidence in the literature or clinical guidelines on when to change antifungal treatment in patients who are receiving prophylaxis or treatment for IA. To try and address this significant gap, an advisory board of experts was convened to develop criteria for the management of IA for use in designing clinical trials, which could also be used in clinical practice. For primary treatment failure, a change in antifungal therapy should be made: (i) when mycological susceptibility testing identifies an organism from a confirmed site of infection, which is resistant to the antifungal given for primary therapy, or a resistance mutation is identified by molecular testing; (ii) at, or after, 8 days of primary antifungal treatment if there is increasing serum galactomannan, or galactomannan positivity in serum, or bronchoalveolar lavage fluid when the antigen was previously undetectable, or there is sudden clinical deterioration, or a new clearly distinct site of infection is detected; and (iii) at, or after, 15 days of primary antifungal treatment if the patient is clinically stable but with >= 2 serum galactomannan measurements persistently elevated compared with baseline or increasing, or if the original lesions on CT or other imaging, show progression by >25% in size in the context of no apparent change in immune status.

Published
2022

23. Mycobacterial infections in adults with haematological malignancies and haematopoietic stem cell transplants: guidelines from the 8th European Conference on Infections in Leukaemia.

Author

UCL - SSS/IREC/SLUC - Pôle St.-Luc, UCL - (SLuc) Service de médecine interne générale, Bergeron, Anne, Mikulska, Malgorzata, De Greef, Julien, Bondeelle, Louise, Franquet, Tomas, Herrmann, Jean-Louis, Lange, Christoph, Spriet, Isabel, Akova, Murat, Donnelly, J Peter, Maertens, Johan, Maschmeyer, Georg, Rovira, Montserrat, Goletti, Delia, de la Camara, Rafael, European Conference on Infections in Leukaemia group, UCL - SSS/IREC/SLUC - Pôle St.-Luc, UCL - (SLuc) Service de médecine interne générale, Bergeron, Anne, Mikulska, Malgorzata, De Greef, Julien, Bondeelle, Louise, Franquet, Tomas, Herrmann, Jean-Louis, Lange, Christoph, Spriet, Isabel, Akova, Murat, Donnelly, J Peter, Maertens, Johan, Maschmeyer, Georg, Rovira, Montserrat, Goletti, Delia, de la Camara, Rafael, and European Conference on Infections in Leukaemia group

Abstract

Mycobacterial infections, both tuberculosis and nontuberculous, are more common in patients with haematological malignancies and haematopoietic stem cell transplant recipients than in the general population-although these infections remain rare. Mycobacterial infections pose both diagnostic and therapeutic challenges. The management of mycobacterial infections is particularly complicated for patients in haematology because of the many drug-drug interactions between antimycobacterial drugs and haematological and immunosuppressive treatments. The management of mycobacterial infections must also consider the effect of delaying haematological management. We surveyed the management practices for latent tuberculosis infection (LTBI) in haematology centres in Europe. We then conducted a meticulous review of the literature on the epidemiology, diagnosis, and management of LTBI, tuberculosis, and nontuberculous mycobacterial infections among patients in haematology, and we formulated clinical guidelines according to standardised European Conference on Infections in Leukaemia (ECIL) methods. In this Review, we summarise the available literature and the recommendations of ECIL 8 for managing mycobacterial infections in patients with haematological malignancies.

Published
2022

24. Epidemiology and Outcome of Fungemia in a Cancer Cohort of the Infectious Diseases Group (IDG) of the European Organization for Research and Treatment of Cancer (EORTC 65031) (vol 61, pg 324, 2015)

Author

Cornely, Oliver A., Gachot, Bertrand, Akan, Hamdi, Bassetti, Matteo, Uzun, Omrun, Kibbler, Christopher, Marchetti, Oscar, de Burghgraeve, Peter, Ramadan, Safaa, Pylkkanen, Liisa, Ameye, Lieveke, Paesmans, Marianne, Donnelly, J. Peter, Cornely, Oliver A., Gachot, Bertrand, Akan, Hamdi, Bassetti, Matteo, Uzun, Omrun, Kibbler, Christopher, Marchetti, Oscar, de Burghgraeve, Peter, Ramadan, Safaa, Pylkkanen, Liisa, Ameye, Lieveke, Paesmans, Marianne, and Donnelly, J. Peter

Published
2022

25. When to change treatment of acute invasive aspergillosis:an expert viewpoint

Author

Slavin, Monica A., Chen, Yee Chun, Cordonnier, Catherine, Cornely, Oliver A., Cuenca-Estrella, Manuel, Donnelly, J. Peter, Groll, Andreas H., Lortholary, Olivier, Marty, Francisco M., Nucci, Marcio, Rex, John H., Rijnders, Bart J.A., Thompson, George R., Verweij, Paul E., White, P. Lewis, Hargreaves, Ruth, Harvey, Emma, Maertens, Johan A., Slavin, Monica A., Chen, Yee Chun, Cordonnier, Catherine, Cornely, Oliver A., Cuenca-Estrella, Manuel, Donnelly, J. Peter, Groll, Andreas H., Lortholary, Olivier, Marty, Francisco M., Nucci, Marcio, Rex, John H., Rijnders, Bart J.A., Thompson, George R., Verweij, Paul E., White, P. Lewis, Hargreaves, Ruth, Harvey, Emma, and Maertens, Johan A.

Abstract

Invasive aspergillosis (IA) is an acute infection affecting patients who are immunocompromised, as a result of receiving chemotherapy for malignancy, or immunosuppressant agents for transplantation or autoimmune disease. Whilst criteria exist to define the probability of infection for clinical trials, there is little evidence in the literature or clinical guidelines on when to change antifungal treatment in patients who are receiving prophylaxis or treatment for IA. To try and address this significant gap, an advisory board of experts was convened to develop criteria for the management of IA for use in designing clinical trials, which could also be used in clinical practice. For primary treatment failure, a change in antifungal therapy should be made: (i) when mycological susceptibility testing identifies an organism from a confirmed site of infection, which is resistant to the antifungal given for primary therapy, or a resistance mutation is identified by molecular testing; (ii) at, or after, 8 days of primary antifungal treatment if there is increasing serum galactomannan, or galactomannan positivity in serum, or bronchoalveolar lavage fluid when the antigen was previously undetectable, or there is sudden clinical deterioration, or a new clearly distinct site of infection is detected; and (iii) at, or after, 15 days of primary antifungal treatment if the patient is clinically stable but with ≥2 serum galactomannan measurements persistently elevated compared with baseline or increasing, or if the original lesions on CT or other imaging, show progression by >25% in size in the context of no apparent change in immune status.

Published
2022

27. Correction to: Epidemiology and Outcome of Fungemia in a Cancer Cohort of the Infectious Diseases Group (IDG) of the European Organization for Research and Treatment of Cancer (EORTC 65031)

Author

Cornely, Oliver A, primary, Gachot, Bertrand, additional, Akan, Hamdi, additional, Bassetti, Matteo, additional, Uzun, Omrun, additional, Kibbler, Christopher, additional, Marchetti, Oscar, additional, de Burghgraeve, Peter, additional, Ramadan, Safaa, additional, Pylkkanen, Liisa, additional, Ameye, Lieveke, additional, Paesmans, Marianne, additional, and Donnelly, J Peter, additional

Published
2022
Full Text
View/download PDF

33. Revised Definitions of Invasive Fungal Disease from the European Organization for Research and Treatment of Cancer/Invasive Fungal Infections Cooperative Group and the National Institute of Allergy and Infectious Diseases Mycoses Study Group (EORTC/MSG) Consensus Group

Author

De Pauw, Ben, Walsh, Thomas J., Donnelly, J. Peter, Stevens, David A., Edwards, John E., Calandra, Thierry, Pappas, Peter G., Maertens, Johan, Lortholary, Olivier, Kauffman, Carol A., Denning, David W., Patterson, Thomas F., Maschmeyer, Georg, Bille, Jacques, Dismukes, William E., Herbrecht, Raoul, Hope, William W., Kibbler, Christopher C., Kullberg, Bart Jan, Marr, Kieren A., Muñoz, Patricia, Odds, Frank C., Perfect, John R., Restrepo, Angela, Ruhnke, Markus, Segal, Brahm H., Sobel, Jack D., Sorrell, Tania C., Viscoli, Claudio, Wingard, John R., Zaoutis, Theoklis, and Bennett, John E.

Published
2008
Full Text
View/download PDF

35. An overview of using fungal DNA for the diagnosis of invasive mycoses

Author

White, P. Lewis, primary, Alanio, Alexandre, additional, Brown, Lottie, additional, Cruciani, Mario, additional, Hagen, Ferry, additional, Gorton, Rebecca, additional, Lackner, Michaela, additional, Millon, Laurence, additional, Morton, C. Oliver, additional, Rautemaa-Richardson, Riina, additional, Barnes, Rosemary A., additional, Donnelly, J Peter, additional, and Loffler, Juergen, additional

Published
2022
Full Text
View/download PDF

37. Empiric vs Preemptive Antifungal Strategy in High-Risk Neutropenic Patients on Fluconazole Prophylaxis: A Randomized Trial of the European Organization for Research and Treatment of Cancer.

Author

Maertens, Johan, Lodewyck, Tom, Donnelly, J Peter, Chantepie, Sylvain, Robin, Christine, Blijlevens, Nicole, Turlure, Pascal, Selleslag, Dominik, Baron, Frédéric, Aoun, Mickael, Heinz, Werner J, Bertz, Hartmut, Ráčil, Zdeněk, Vandercam, Bernard, Drgona, Lubos, Coiteux, Valerie, Llorente, Cristina Castilla, Schaefer-Prokop, Cornelia, Paesmans, Marianne, and Ameye, Lieveke

Subjects
MYELODYSPLASTIC syndromes, ANTIFUNGAL agents, CLINICAL trials, CONFIDENCE intervals, CHEST X rays, CASPOFUNGIN, CANCER chemotherapy, NEUTROPENIA, PATIENTS, MEDICAL screening, RISK assessment, RANDOMIZED controlled trials, SURVIVAL analysis (Biometry), DESCRIPTIVE statistics, RESEARCH funding, MYCOSES, FLUCONAZOLE, HEMATOPOIETIC stem cell transplantation, STATISTICAL sampling, COMPUTED tomography, CHEMOPREVENTION, TRANSPLANTATION of organs, tissues, etc., PATIENT safety, DISEASE risk factors
Abstract

Background Empiric antifungal therapy is considered the standard of care for high-risk neutropenic patients with persistent fever. The impact of a preemptive, diagnostic-driven approach based on galactomannan screening and chest computed tomography scan on demand on survival and on the risk of invasive fungal disease (IFD) during the first weeks of high-risk neutropenia is unknown. Methods Patients with acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS) and allogeneic hematopoietic cell transplant recipients were randomly assigned to receive caspofungin empirically (arm A) or preemptively (arm B), while receiving fluconazole 400 mg daily prophylactically. The primary end point of this noninferiority study was overall survival (OS) 42 days after randomization. Results Of 556 patients recruited, 549 were eligible: 275 in arm A and 274 in arm B. Eighty percent of the patients had AML or MDS requiring high-dose chemotherapy, and 93% of them were in the first induction phase. At day 42, the OS was not inferior in arm B (96.7%; 95% confidence interval [CI], 93.8%–98.3%) when compared with arm A (93.1%; 95% CI, 89.3%–95.5%). The rates of IFDs at day 84 were not significantly different, 7.7% (95% CI, 4.5%–10.8%) in arm B vs 6.6% (95% CI, 3.6%–9.5%) in arm A. The rate of patients who received caspofungin was significantly lower in arm B (27%) than in arm A (63%; P <.001). Conclusions The preemptive antifungal strategy was safe for high-risk neutropenic patients given fluconazole as prophylaxis, halving the number of patients receiving antifungals without excess mortality or IFDs. Clinical Trials Registration. NCT01288378; EudraCT 2010-020814-27. [ABSTRACT FROM AUTHOR]

Published
2023
Full Text
View/download PDF

39. Contributors

Author

Aagaard, Kjersti, primary, Abrahamian, Fredrick M., additional, Allos, Ban Mishu, additional, Andes, David R., additional, Aoki, Fred Y., additional, Apicella, Michael A., additional, Ard, Kevin L., additional, Arias, Cesar A., additional, Aronoff, David M., additional, Augenbraun, Michael H., additional, Averhoff, Francisco, additional, Azar, Dimitri T., additional, Baddour, Larry M., additional, Baden, Lindsey R., additional, Baker, Carol J., additional, Ballard, Ronald C., additional, Barber, Gerard R., additional, Barnes, Scott D., additional, Barouch, Dan H., additional, Barrett, Alan D., additional, Barshak, Miriam Baron, additional, Basavaraju, Sridhar V., additional, Batteiger, Byron E., additional, Baum, Stephen G., additional, Bayer, Arnold S., additional, Beckham, J. David, additional, Beekmann, Susan E., additional, Bell, Beth P., additional, Bennett, John E., additional, Bente, Dennis A., additional, Berbari, Elie F., additional, Berman, Jonathan, additional, Bertino, Joseph S., additional, Bhimraj, Adarsh, additional, Birdsall, Holly H., additional, Bisno, Alan L., additional, Blackburn, Brian G., additional, Blanton, Lucas S., additional, Blaser, Martin J., additional, Bleck, Thomas P., additional, Blijlevens, Nicole M.A., additional, Bobak, David A., additional, Bonnez, William, additional, Boothroyd, John C., additional, Borio, Luciana L., additional, Bosque, Patrick J., additional, Bower, John, additional, Bradsher, Robert W., additional, Brook, Itzhak, additional, Brown, Kevin E., additional, Brown, Patricia D., additional, Brown-Elliott, Barbara A., additional, Bruhn, Roberta L., additional, Bryant, Amy E., additional, Burd, Eileen M., additional, Burns, Jane C., additional, Bush, Larry M., additional, Calderwood, Stephen B., additional, Cano, Luz Elena, additional, Carpenter, Charles C.J., additional, Caserta, Mary T., additional, Castagnola, Elio, additional, Chaisson, Richard E., additional, Chambers, Henry F., additional, Chapman, Stephen J., additional, Chappell, James D., additional, Chen, Lea Ann, additional, Chen, Sharon C-A, additional, Chow, Anthony W., additional, Clark, Rebecca A., additional, Cohen, Jeffrey I., additional, Cohen, Myron S., additional, Cohen-Poradosu, Ronit, additional, Cohn, Susan E., additional, Connors, Mark, additional, Corey, Lawrence, additional, Cottrell, Mackenzie L., additional, Cover, Timothy L., additional, Cox, Heather L., additional, Craig, William A., additional, Crossley, Kent B., additional, Crumpacker, Clyde S., additional, Curran, James W., additional, Currie, Bart J., additional, D'Agata, Erika, additional, Damon, Inger K., additional, Darouiche, Rabih O., additional, DeBiasi, Roberta L., additional, Deepe, George S., additional, del Rio, Carlos, additional, Delemos, Andrew S., additional, DeLeo, Frank R., additional, DeMuri, Gregory P., additional, Densen, Peter, additional, Dermody, Terence S., additional, Dewar, Robin, additional, Diaz, James H., additional, Dieffenbach, Carl W., additional, Dienstag, Jules L., additional, Doi, Yohei, additional, Dolin, Raphael, additional, Donnelly, J. Peter, additional, Donnenberg, Michael S., additional, Donowitz, Gerald R., additional, Dormitzer, Philip R., additional, Drake, James M., additional, Dumler, J. Stephen, additional, Dummer, J. Stephen, additional, DuPont, Herbert L., additional, Durack, David T., additional, Durand, Marlene L., additional, Edelstein, Paul H., additional, Edmond, Michael B., additional, Edwards, John E., additional, Edwards, Morven S., additional, Eliopoulos, George M., additional, Ellison, Richard T., additional, Endy, Timothy P., additional, Engleberg, N. Cary, additional, Erdem, Hakan, additional, Ernst, Joel D., additional, Ernst, Peter B., additional, Fairhurst, Rick M., additional, Fairley, Jessica K., additional, Falkow, Stanley, additional, Falsey, Ann R., additional, Fauci, Anthony S., additional, Fekete, Thomas, additional, Fey, Paul D., additional, Fine, Steven M., additional, Fitzgerald, Daniel W., additional, Flores, Anthony R., additional, Forster, Derek, additional, Fowler, Vance G., additional, Freedman, David O., additional, Friedlander, Arthur M., additional, Galgiani, John N., additional, Gallin, John I., additional, Gallo, Robert C., additional, Gandhi, Tejal N., additional, Garrett, Wendy S., additional, Gaydos, Charlotte A., additional, Geisbert, Thomas W., additional, Gelfand, Jeffrey A., additional, Gelone, Steven P., additional, Gerding, Dale N., additional, Gershon, Anne A., additional, Gilsdorf, Janet R., additional, Goldstein, Ellie J.C., additional, Gordin, Fred M., additional, Graman, Paul S., additional, Grayson, M. Lindsay, additional, Greene, Jeffrey Bruce, additional, Griffin, Patricia M., additional, Griffith, David E., additional, Guerrant, Richard L., additional, Gul, H. Cem, additional, Haake, David A., additional, Haas, David W., additional, Haines, Charles, additional, Hall, Caroline Breese, additional, Hallak, Joelle, additional, Halperin, Scott A., additional, Hammerschlag, Margaret R., additional, Haque, Rashidul, additional, Harris, Jason B., additional, Hawkins, Claudia, additional, Hay, Roderick J., additional, Hedberg, Craig W., additional, Henderson, David K., additional, Henderson, Donald A., additional, High, Kevin P., additional, Hill, Adrian V.S., additional, Hill, David R., additional, Hinman, Alan R., additional, Hirsch, Martin S., additional, Hodowanec, Aimee, additional, Hohl, Tobias M., additional, Holland, Steven M., additional, Holzman, Robert S., additional, Hook, Edward W., additional, Hooper, David C., additional, Hooton, Thomas M., additional, Horowitz, Harold W., additional, Horsburgh, C. Robert, additional, Horton, James M., additional, Hospenthal, Duane R., additional, Hsueh, Kevin, additional, Hughes, James M., additional, Hynes, Noreen A., additional, Iovine, Nicole M., additional, Iredell, Jonathan R., additional, Ison, Michael G., additional, Janda, J. Michael, additional, Janoff, Edward N., additional, Johannsen, Eric C., additional, Kashuba, Angela D.M., additional, Kasper, Dennis L., additional, Kaye, Donald, additional, Kaye, Keith S., additional, Kaye, Kenneth M., additional, Kazura, James W., additional, Keystone, Jay S., additional, Khabbaz, Rima, additional, Khan, David A., additional, Khudyakov, Yury, additional, Kim, Rose, additional, King, Charles H., additional, Kirchhoff, Louis V., additional, Klein, Jerome O., additional, Klompas, Michael, additional, Knoll, Bettina M., additional, Knowlton, Kirk U., additional, Koehler, Jane E., additional, Kohlhoff, Stephan A., additional, Könönen, Eija, additional, Kontoyiannis, Dimitrios P., additional, Koralnik, Igor J., additional, Korpe, Poonum S., additional, Koshy, Anita A., additional, Kovacs, Joseph A., additional, Kozarsky, Phyllis, additional, Krieger, John, additional, Kroger, Andrew T., additional, Kuehnert, Matthew J., additional, Kumar, Nalin M., additional, Kuruvilla, Merin Elizabeth, additional, LaRocque, Regina C., additional, Leggett, James E., additional, Legido-Quigley, Helena, additional, Levett, Paul N., additional, Levine, Donald P., additional, Levison, Matthew E., additional, Levitt, Alexandra, additional, Lewis, Russell E., additional, Liles, W. Conrad, additional, Lima, Aldo A.M., additional, Limaye, Ajit P., additional, Lipkin, W. Ian, additional, Litman, Nathan, additional, Lorber, Bennett, additional, Luna, Ruth Ann, additional, MacDougall, Conan, additional, Roy, Rob, additional, Mackowiak, Philip A., additional, Madoff, Lawrence C., additional, Magill, Alan J., additional, Maguire, James H., additional, Maldarelli, Frank, additional, Markoff, Lewis, additional, Marrazzo, Jeanne M., additional, Marrie, Thomas J., additional, Marth, Thomas, additional, Martin, David H., additional, Martin, Gregory J., additional, Marty, Francisco M., additional, Maslow, Melanie Jane, additional, Masur, Henry, additional, Mawle, Alison, additional, Mayer, Kenneth H., additional, McBride, John T., additional, McCarthy, James S., additional, McCormack, William M., additional, McGowan, Catherine C., additional, McIntosh, Kenneth, additional, Mead, Paul S., additional, Mikulska, Malgorzata, additional, Miller, Robert F., additional, Miller, Samuel I., additional, Mitchell, David H., additional, Modlin, John F., additional, Mody, Rajal K., additional, Moellering, Robert C., additional, Moffa, Matthew, additional, Moir, Susan, additional, Montoya, José G., additional, Moore, Thomas A., additional, Moreillon, Philippe, additional, Morris, J. Glenn, additional, Morse, Caryn Gee, additional, Moseley, Robin, additional, Munford, Robert S., additional, Murphy, Edward L., additional, Murphy, Timothy F., additional, Murray, Barbara E., additional, Murray, Clinton K., additional, Murray, Patrick R., additional, Musher, Daniel M., additional, Nagel, Jerod L., additional, Nannini, Esteban C., additional, Narezkina, Anna, additional, Nash, Theodore E., additional, Nauseef, William M., additional, Nayak, Jennifer L., additional, Neill, Marguerite A., additional, O'Donnell, Judith A., additional, Ohl, Christopher A., additional, Okhuysen, Pablo C., additional, Onderdonk, Andrew B., additional, Opal, Steven M., additional, Orenstein, Walter A., additional, Osmon, Douglas R., additional, Osterholm, Michael T., additional, Ostroff, Stephen M., additional, Oxman, Michael N., additional, Paessler, Slobodan, additional, Page, Andrea V., additional, Pai, Manjunath P., additional, Palmore, Tara N., additional, Palraj, Raj, additional, Pappas, Peter G., additional, Pasternack, Mark S., additional, Patterson, Thomas F., additional, Pavan-Langston, Deborah, additional, Pegues, David A., additional, Penn, Robert L., additional, Perfect, John R., additional, Perlman, Stanley, additional, Petersen, Brett W., additional, Peterson, Phillip K., additional, Petri, William A., additional, Petti, Cathy A., additional, Philips, Jennifer A., additional, Philley, Julie V., additional, Phillips, Michael, additional, Pickering, Larry K., additional, Piot, Peter, additional, Pogue, Jason M., additional, Pop-Vicas, Aurora, additional, Portal-Celhay, Cynthia, additional, Powers, John H., additional, Price, Richard N., additional, Que, Yok-Ai, additional, Radolf, Justin D., additional, Ram, Sanjay, additional, Raoult, Didier, additional, Ravdin, Jonathan I., additional, Ray, Stuart C., additional, Reboli, Annette C., additional, Reitz, Marvin S., additional, Relman, David A., additional, Renault, Cybèle A., additional, Restrepo, Angela, additional, Rex, John H., additional, Rhee, Elizabeth G., additional, Roberts, Norbert J., additional, Romero, José R., additional, Rothman, Alan L., additional, Roy, Craig R., additional, Ruoff, Kathryn L., additional, Rupp, Mark E., additional, Rupprecht, Charles E., additional, Russo, Thomas A., additional, Rutala, William A., additional, Ryan, Edward T., additional, Safdar, Amar, additional, Sajadi, Mohammad M., additional, Salazar, Juan C., additional, Sarria, Juan Carlos, additional, Savoia, Maria C., additional, Sax, Paul E., additional, Scheld, W. Michael, additional, Schiffer, Joshua T., additional, Schlossberg, David, additional, Schneider, Thomas, additional, Schuchat, Anne, additional, Schwebke, Jane R., additional, Sears, Cynthia L., additional, Segal, Leopoldo N., additional, Sendi, Parham, additional, Sepkowitz, Kent A., additional, Septimus, Edward J., additional, Seregin, Alexey, additional, Shulman, Stanford T., additional, Siberry, George K., additional, Siddiqi, Omar K., additional, Sifri, Costi D., additional, Simberkoff, Michael S., additional, Simonetti, Francesco R., additional, Singh, Kamaljit, additional, Singh, Nina, additional, Singh, Upinder, additional, Sinner, Scott W., additional, Sivapalasingam, Sumathi, additional, Slater, Leonard N., additional, Smulian, A. George, additional, Sobel, Jack D., additional, Sohail, M. Rizwan, additional, Soper, David E., additional, Sorrell, Tania C., additional, Steckelberg, James M., additional, Steere, Allen C., additional, Steigbigel, Neal H., additional, Steinberg, James P., additional, Stephens, David S., additional, Sterling, Timothy R., additional, Stevens, David A., additional, Stevens, Dennis L., additional, Strahilevitz, Jacob, additional, Stratton, Charles W., additional, Suffredini, Anthony F., additional, Suh, Kathryn N., additional, Sulkowski, Mark S., additional, Swartz, Morton N., additional, Talbot, Thomas R., additional, Tan, C. Sabrina, additional, Tan, Ming, additional, Thio, Chloe Lynne, additional, Thomas, David L., additional, Thomas, Lora D., additional, Thomas, Stephen J., additional, Thorner, Anna R., additional, María Tobón, Angela, additional, Tramont, Edmund C., additional, Treanor, John J., additional, Trubiano, Jason, additional, Tsibris, Athe M.N., additional, Tunkel, Allan R., additional, Turner, Ronald B., additional, Tyler, Kenneth L., additional, Uluer, Ahmet, additional, van de Beek, Diederik, additional, van der Velden, Walter J.F.M., additional, Vannier, Edouard G., additional, Van, Trevor C., additional, Versalovic, James, additional, Viscoli, Claudio, additional, Wald, Ellen R., additional, Waldor, Matthew K., additional, Walker, David H., additional, Wallace, Richard J., additional, Walsh, Edward E., additional, Walsh, Stephen R., additional, Walzer, Peter D., additional, Wanke, Christine A., additional, Warren, Cirle A., additional, Washburn, Ronald G., additional, Waters, Valerie, additional, Weber, David J., additional, Weiden, Michael D., additional, Weinberg, Geoffrey A., additional, Weisdorf, Daniel J., additional, Weiss, Louis M., additional, Welch, David F., additional, Wellems, Thomas E., additional, Wenzel, Richard P., additional, Wharton, Melinda, additional, White, A. Clinton, additional, Whitley, Richard J., additional, Wilson, Walter R., additional, Wortmann, Glenn W., additional, Wright, William F., additional, Young, Jo-Anne H., additional, Young, Vincent B., additional, Yun, Nadezhda, additional, Zimmerli, Werner, additional, Zinner, Stephen H., additional, and Zurlo, John J., additional

Published
2015
Full Text
View/download PDF

45. Ibrutinib Is a Newly Recognized Host Factor for the Definition of Probable Invasive Pulmonary Mold Disease, Based on Off-target Effects, Unrelated to Its B-cell Immunosuppressant Activity Reply

Author

Wingard, John R, Maertens, Johan, Pagano, Livio, Chen, Sharon C-A, Pappas, Peter G, and Donnelly, J Peter

Subjects
Science & Technology, Infectious Diseases, Immunology, TYROSINE KINASE, Life Sciences & Biomedicine, Microbiology, THERAPY
Abstract

ispartof: CLINICAL INFECTIOUS DISEASES vol:71 issue:12 pages:3266-3266 ispartof: location:United States status: published

Published
2020

50. Revised definitions of invasive fungal disease from the European Organization for Research and Treatment of Cancer/Invasive Fungal Infections Cooperative Group and the National Institute of Allergy and Infectious Diseases Mycoses Study Group (EORTC/MSG) consensus group

Author

Pauw, Ben De, Walsh, Thomas J., Donnelly, J. Peter, Stevens, David A., Edwards, John E., Calandra, Thierry, Pappas, Peter G., Maertens, Johan, Lortholary, Olivier, Kauffman, Carol A., Denning, David W., Patterson, Thomas F., Maschmeyer, Georg, Bille, Jacques, Dismukes, William E., Herbrecht, Raoul, Hope, William W., Kibbler, Christopher C., Kullberg, Bart Jan, Marr, Kieren A., Munoz, Patricia, Odds, Frank C., Perfect, John R., Restrepo, Angela, Ruhnke, Markus, Segal, Brahm H., Sobel, Jack D., Sorrell, Tania C., Viscoli, Claudio, Wingard, John R., Zaoutis, Theoklis, and Bennett, John E.

Subjects
Mycoses -- Prognosis, Mycoses -- Research, Cancer -- Research, Cancer -- Care and treatment, Health, Health care industry
Published
2008

Catalog

Books, media, physical & digital resources
See catalog results